HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ronald D. Curran Constantine Mavroudis Carl L. Backer David L. Wessel Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Curran, R. D. Articles by Wessel, D. L. Search for Related Content PubMed PubMed Citation Articles by Curran, R. D. Articles by Wessel, D. L.

Ann Thorac Surg 1995;60:1765-1771
© 1995 The Society of Thoracic Surgeons

---

Articles

Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension

^a Divisions of Cardiovascular-Thoracic Surgery and Cardiology, Children's Memorial Hospital, USA
^b Departments of Surgery and Pediatrics, Northwestern University Medical School, Chicago, Illinois, USA

Accepted for publication August 9, 1995.

^* Address reprint requests to Dr Mavroudis, Division of Cardiovascular-Thoracic Surgery, Children's Memorial Hospital, 2300 Children's Plaza—M/C 22, Chicago, IL 60614.

Background.: Endothelium-derived nitric oxide (NO) is a potent vasodilator and a major mediator of pulmonary vascular tone.

Methods.: Five infants underwent a trial of inhaled NO with hemodynamic monitoring in the operating room after atrioventricular canal repair. An additional 15 patients with congenital heart disease and refractory pulmonary hypertension were treated with inhaled NO for 1 day to 10 days postoperatively.

Results.: In the 5 infants with atrioventricular canal, corrective surgical intervention and conventional therapy (hyperventilation, inspired oxygen fraction of 0.80, and inotropic agents) lowered mean pulmonary artery pressure from 49.5 ± 10.5 to 20.0 ± 2.2 mm Hg (p < 0.001). Adding inhaled NO further decreased mean pulmonary artery pressure to 18.0 ± 2.8 mm Hg (p = not significant). Inhaled NO had no effect on ventricular function curves (inflow occlusion) in this group. In the 15 patients with refractory postoperative pulmonary hypertension, 11 had a favorable response to inhaled NO, with a decrease in mean pulmonary artery pressure from 30.9 ± 5.8 to 23.1 ± 5.4 mm Hg (p < 0.01) in 8 patients with pulmonary artery catheters.

Conclusions.: These studies demonstrate that inhaled NO has minimal beneficial effect on pulmonary artery pressure or cardiac output in infants after repair of atrioventricular canal. Inhaled NO is effective in decreasing PAP postoperatively in select patients with congenital heart disease and pulmonary hypertension refractory to conventional therapeutic modalities.

This article has been cited by other articles:

				S. Nemoto, T. Sasaki, H. Ozawa, T. Katsumata, K. Kishi, K. Okumura, Y. Mori, and O. Umegaki Oral sildenafil for persistent pulmonary hypertension early after congenital cardiac surgery in children Eur J Cardiothorac Surg, July 1, 2010; 38(1): 71 - 77. [Abstract] [Full Text] [PDF]

				J. E. Lee, S. C. Hillier, and C. A. Knoderer Use of Sildenafil to Facilitate Weaning From Inhaled Nitric Oxide in Children With Pulmonary Hypertension Following Surgery for Congenital Heart Disease J Intensive Care Med, September 1, 2008; 23(5): 329 - 334. [Abstract] [PDF]

				T. Karamlou, R. Gurofsky, E. Al Sukhni, J. G. Coles, W. G. Williams, C. A. Caldarone, G. S. Van Arsdell, and B. W. McCrindle Factors Associated With Mortality and Reoperation in 377 Children With Total Anomalous Pulmonary Venous Connection Circulation, March 27, 2007; 115(12): 1591 - 1598. [Abstract] [Full Text] [PDF]

				P. Namachivayam, U. Theilen, W. W. Butt, S. M. Cooper, D. J. Penny, and L. S. Shekerdemian Sildenafil Prevents Rebound Pulmonary Hypertension after Withdrawal of Nitric Oxide in Children Am. J. Respir. Crit. Care Med., November 1, 2006; 174(9): 1042 - 1047. [Abstract] [Full Text] [PDF]

				C. L. Hancock Friesen, D. Zurakowski, R. R. Thiagarajan, J. M. Forbess, P. J. del Nido, J. E. Mayer, and R. A. Jonas Total Anomalous Pulmonary Venous Connection: An Analysis of Current Management Strategies in a Single Institution Ann. Thorac. Surg., February 1, 2005; 79(2): 596 - 606. [Abstract] [Full Text] [PDF]

				B.H. Jiang, J. Maruyama, A. Yokochi, H. Amano, Y. Mitani, and K. Maruyama Correlation of inhaled nitric-oxide induced reduction of pulmonary artery pressure and vascular changes Eur. Respir. J., July 1, 2002; 20(1): 52 - 58. [Abstract] [Full Text] [PDF]

				L. Lindberg, A. K. Olsson, P. Jogi, and C. Jonmarker How common is severe pulmonary hypertension after pediatric cardiac surgery? J. Thorac. Cardiovasc. Surg., June 1, 2002; 123(6): 1155 - 1163. [Abstract] [Full Text] [PDF]

				R. W. Day, J. A. Hawkins, E. C. McGough, K. L. Crezee, and G. S. Orsmond Randomized controlled study of inhaled nitric oxide after operation for congenital heart disease Ann. Thorac. Surg., June 1, 2000; 69(6): 1907 - 1912. [Abstract] [Full Text] [PDF]

				I. Schulze-Neick, D. J. Penny, M. L. Rigby, C. Morgan, A. Kelleher, P. Collins, J. Li, A. Bush, E. A. Shinebourne, and A. N. Redington L-Arginine and Substance P Reverse the Pulmonary Endothelial Dysfunction Caused by Congenital Heart Surgery Circulation, August 17, 1999; 100(7): 749 - 755. [Abstract] [Full Text] [PDF]